Search
Results: 2
Cabozantinib as a second-line treatment option in hepatocellular carcinoma
Alberto D’Angelo, Navid Sobhani, Stefan Bagby, Andrea Casadei-Gardini, Giandomenico Roviello
Jun 02, 2020
Introduction: Hepatocellular carcinoma (HCC) is one of the most frequent tumors affecting the gastrointestinal tract and a universal cause of morbidity and mortality. Cabozantinib is a strong multi-inhibitor of receptor...
Cabozantinib hepatocellular carcinoma Immunotherapy liver dysfunction population pharmacokinetics Precision Medicine second-line toxicity Treatment tyrosine kinase inhibitors (TKI) /dk/atira/pure/subjectarea/asjc/3000 name=Pharmacology, Toxicology and Pharmaceutics(all) /dk/atira/pure/subjectarea/asjc/2700/2736 name=Pharmacology (medical)
Cabozantinib as a second-line treatment option in hepatocellular carcinoma
Alberto D’Angelo, Navid Sobhani, Stefan Bagby, Andrea Casadei-Gardini, Giandomenico Roviello
Jun 02, 2020
Introduction: Hepatocellular carcinoma (HCC) is one of the most frequent tumors affecting the gastrointestinal tract and a universal cause of morbidity and mortality. Cabozantinib is a strong multi-inhibitor of receptor...
Cabozantinib hepatocellular carcinoma Immunotherapy liver dysfunction population pharmacokinetics Precision Medicine second-line toxicity Treatment tyrosine kinase inhibitors (TKI) /dk/atira/pure/subjectarea/asjc/3000 name=Pharmacology, Toxicology and Pharmaceutics(all) /dk/atira/pure/subjectarea/asjc/2700/2736 name=Pharmacology (medical)